Sissi V. Pham
For me the Delta glyph represents the words of Socrates, “Let him that would move the world first move himself.” I have found that when I am out of my comfort zone – I am learning, growing, doing and living at my best. As such, I’m driven to help our clients anticipate, embrace and aim for change to further their quest to transform healthcare.
Sissi Pham is a founder, CEO & CFO of AESARA. Prior to AESARA, Sissi provided Market Access consulting solutions to pharmaceutical, biotechnology and device partners. Sissi began her career with a major pharmaceutical company in the UK and at the end of her tenure she managed the global and health outcomes and market access support function based in the US. She is experienced in designing and implementing frameworks for robust Market Access strategies, timely and relevant evidence generation plan, and effective communication of Market Access information.
Sissi has also served on the benefits working group of the Pharmaceutical Research and Manufacturers of America that built a general framework for translating medical benefits into new stakeholder-centric value propositions during drug development. In addition, she has served as the Institutional Council Chair for the International Society of Pharmaceutical Outcomes Research, where she initiated the development of a supplement reviewing trends in health technology assessments (HTA) around the world that was published in the May 2009 edition of Value in Health. This publication has contributed to the comparative effectiveness dialogue in the US and the evolution of HTA.
Sissi has an appointment of Associate Clinical Professor at the College of Pharmacy, University of Arizona. Sissi’s Market Access experiences were acquired through her career experiences in pharmacoeconomics fellowship, pharmaceutical industry health outcomes research and market support functions, and strategic market access consulting.
Presented HIV Drug Impact Model to Office Management and Budget (OMB), agency of US federal government, to advocate for funding for the shift from mono-therapy to break-through triple combination HIV therapy. This contributed to the advocacy initiative resulting in an emergency funding of $50 Million from President Bill Clinton in 1996. The HIV Drug Impact Model continued for many years after to be use for national and local Aids Drug Assistance Program (ADAP) funding determination.
- O’Donnell JC, Pham SV, Pashos CL, et al. Health Technology Assessment: Lessons Learned from Around the World – An Overview. Value in Health. 2009;12 Suppl 2:S1-S5
- Stang PE, Pham SV, Kinchen K, Raff SB, Mussen F, Gondek F. The identification of benefit in medical intervention: an overview and suggestions for process. American Journal of Therapeutics. 2008;15:495-503.
- Mauskopf JA, Tolson JM, Simpson KN, Pham SV, Albright J. Impact of Zidovudine-Based Triple Combination Therapy on an AIDS Drug Assistance Program. Journal of Acquired Immune Deficiency Syndromes. 2000;23:302-313.
Areas of Expertise
- Strategic and Business Planning
- US Market Support
- Launch Strategic Planning
- Promotional Communication
- Healthcare Policy
- Doctor of Pharmacy, University of Arizona
- Pharmacoeconomics Research Fellowship, University of Arizona and Glaxo